The Selective Peroxisome Proliferator-Activated Receptor Alpha Modulator (SPPARMα) Concept

NEW HORIZONS FOR RESIDUAL VASCULAR RISK?
SESSION 1 Beyond conventional risk factors: Why hypertriglyceridemia matters?

Chairs: Jean-Pierre Després (Canada) & Ruth McPherson (Canada)

9:00 - 9:10 a.m Raul Santos (Brazil) & Jean-Charles Fruchart (France)
Why do we need this consensus?

9:10 - 9:30 a.m Marjaarita Taskinen (Finland)
The obesity crisis: what drives dyslipidemia?

9:30 - 9:50 a.m Anne Tybjærg-Hansen (Danmark)
What’s new in hypertriglyceridemia: insights from genetics studies

DISCUSSION 1 All participants

• 9:50 - 10:05 a.m Hypertriglyceridaemia – is it causal for cardiovascular disease? What is the evidence?

• 10:05 - 10:20 a.m What lipid parameter(s) should be the focus for dyslipidaemia management?

SESSION 2 Defining the profile of a SPPARMα: preclinical data

Chairs: Michel Farnier (France) & G. Watts (Australia)

10:45 - 11:05 a.m Jean-Charles Fruchart (France)
Selective PPARα modulation: Understanding the concept and its therapeutic potential

11:05 - 11:25 a.m Hitoshi Shimano (Japan)
Molecular association model of PPARα and its new specific and efficient ligand, pemafibrate: Structural basis for SPPARMα

11:25 - 11:45 a.m Tatsuhiko Kodama (Japan)
Transcriptome analysis of a novel SPPARMα: defining and differentiating the profile of activity

11:45 - 12:05 a.m Peter Libby (USA)
Anti-inflammatory effects of SPPARMα

DISCUSSION 2 All participants

• 12:05 - 12:20 a.m How do preclinical studies inform understanding of the SPPARMα concept?

• 12:20 - 12:35 p.m Based on its profile of activity, what are the potential therapeutic indications for SPPARMα?

• 12:35 - 12:50 p.m Do anti-inflammatory effects of a SPPARMα differentiate this from a PPARα agonist?

SESSION 3 Do clinical trials provide proof of the SPPARMα concept?

Chairs: Henry Ginsberg (USA) & Alberto Zambon (Italy)

2:00 - 2:20 p.m Børge Nordestgaard (Danmark)
Effects of a SPPARMα on atherogenic triglyceride-rich lipoproteins at increased concentrations

2:20 - 2:40 p.m Shun Ishibashi (Japan)
Effects of a SPPARMα on lipid and glucose metabolism in type 2 diabetes and hypertriglyceridemia

2:40 - 3:00 p.m Koutaro Yokote (Japan)
Overview of clinical trials with a SPPARMα in patients with dyslipidaemia: Japanese and European experience

DISCUSSION 3 All participants

• 3:00 - 3:15 p.m Do the properties of a SPPARMα confer advantages over current options in the management of dyslipidemia?

• 3:15 - 3:30 p.m What is the risk versus benefit ratio - does this differ from a PPARα agonist?

• 3:30 - 3:45 p.m What are the outstanding questions regarding SPPARMα?

• 3:45 - 4:00 p.m Could a SPPARMα have a role in other clinical settings?
**SESSION 4 SPPARMα:**

**New horizons for residual cardiovascular risk?**

*Chairs: Robert Eckel (USA) & Fredrik Karpe (United Kingdom)*

**4:30 - 4:50 p.m**  
**Masanori Aikawa (USA)**  
Anti-atherosclerotic effects of a SPPARMα: insights from preclinical studies

**4:50 - 5:10 p.m**  
**Shizuya Yamashita (Japan)**  
Effect of a SPPARMα on macrophage cholesterol efflux to HDL

**5:10 - 5:30 p.m**  
**Aruna Pradhan (USA)**  
PROMINENT and PROMINENT substudy: a rationale and update on progress

**DISCUSSION 4 All participants**

- **5:30 - 5:45 p.m**  
  Do the anti-atherosclerotic effects of a SPPARMα differentiate this from a PPARα agonist?

- **5:45 - 6:00 p.m**  
  What is the mechanism(s) of SPPARMα anti-atherosclerotic activity: lipid or inflammatory effects or both?

- **6:00 - 6:15 p.m**  
  What is the role of SPPARMα in diabetes-related microvascular complications

**6:15 - 6:30 p.m**  
**Conclusions and next steps**  
*Chairs: Jean-Charles Fruchart (France) & Phil Barter (Australia)*

**END**